Why 2/5: It establishes new reporting requirements for an existing public health program, increasing transparency rather than creating immediate operational changes.
The Department of Health will now be required to submit quarterly and annual reports detailing the distribution of opioid antagonists and estimating future program costs. This measure aims to enhance transparency and accountability for Virginia's program providing life-saving overdose reversal drugs.
Update
Constitutional reading dispensed (on 2nd reading) (40-Y 0-N 0-A)
Update
Passed by for the day (Voice Vote)
Third reading
Read third time
Update
Education and Health Substitute agreed to
Substitute adopted
Engrossed by Senate - committee substitute
Passed a chamber
Passed Senate with substitute Block Vote (40-Y 0-N 0-A)
Substitute adopted
Senate substitute agreed to by House (95-Y 1-N 0-A)
Enrolled
Enrolled
Passed a chamber
Bill text as passed House and Senate (HB1063ER)
This bill has passed its votes and is headed to the Governor's desk. You still have a say — the Governor's office reads messages before deciding whether to sign.
New to all this? See how a bill becomes law →
Summarized from the official bill text (“Opioid antagonist; distribution program, reports.”) · Read the actual bill →
Update
Fiscal Impact Statement from Department of Planning and Budget (HB1063)
Passed a chamber
Signed by Speaker
Passed a chamber
Signed by President
Enrolled
Enrolled Bill communicated to Governor on March 14, 2026
Sent to the Governor
Governor's Action Deadline 11:59 p.m., April 13, 2026
Signed into law
Approved by Governor-Chapter 729 (effective 7/1/2026)